EUVIMEDEUVIMED entdecken
Open Access

Safety and Performance Evaluation of a Clinical Decision Support System for Imatinib Therapeutic Drug Monitoring: In Silico Study

Yuan James Pétermann, Roberto Rigamonti, Paul Thoueille, Junrui Chen, Lavinia Alberi, Alexandra Simon, François Veuve, Eva Choong, Bruno Da Rocha Carvalho, Sandro Carrara, François R Girardin, Thierry Buclin und 3 weitere

JMIR Medical Informatics · 21.10.2026 · 14 · e93304-e93304

DOI: 10.2196/93304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JMIR Medical Informatics, online erschienen am 21.10.2026. Verfasst von Yuan James Pétermann und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital of Lausanne and University of Lausanne, Rue du Bugnon 19,…. Hauptthemen laut MEDLINE: Imatinib Mesylate, Drug Monitoring, Decision Support Systems, Clinical. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Therapeutic drug monitoring (TDM) aims to optimize clinical outcomes but is hindered by logistical delays and susceptibility to data errors. Integrating model-informed precision dosing with point-of-care testing, fortified by rule-based validation and alerts, forms a transformative clinical decision support system (CDSS) essential for securing this complex workflow.

Objective

This study evaluates, in silico , the effectiveness of a rule-based CDSS for imatinib in detecting data-quality issues and optimizing therapeutic dosing, compared with a human TDM expert.

Methods

We simulated a set of 60 virtual patients using a previously developed population pharmacokinetic model and deliberately enriched it with data-quality errors (eg, timing inaccuracies and reporting errors) to stress-test system resilience. We compared CDSS and TDM expert performances based on their error-detection capabilities and the clinical impact on therapeutic target attainment and safety.

Results

The CDSS and the expert demonstrated comparable error-detection capabilities. The CDSS showed numerically higher sensitivity (53%, 95% CI 35%‐70% vs 45%, 95% CI 30%‐61%) and lower specificity (83%, 95% CI 63%‐95% vs 100%, 95% CI 81%‐100%). Clinically, the CDSS demonstrated significantly higher rates of target attainment than the expert (33/60, 55% vs 22/60, 37%; P =.046). However, the CDSS resulted in 5 detrimental outcomes against 1 for the TDM expert, in which patients initially within the target range fell outside it.

Conclusions

The CDSS demonstrated high efficacy in optimizing imatinib exposure while serving as a robust digital gatekeeper. While active optimization drives higher efficacy, a few observed detrimental cases highlight that algorithmic safety remains contingent on data integrity. This proof-of-concept study validates the CDSS architecture as a prerequisite for future prospective clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateDrug MonitoringDecision Support Systems, ClinicalHumansComputer SimulationAntineoplastic Agents

Stichwörter der Autor:innen

clinical decision support systemimatinibmodel-informed precision dosingoncologypharmacokineticspoint-of-carepopulation pharmacokinetictherapeutic drug monitoring

Substanzen

Imatinib MesylateAntineoplastic Agents

Autor:innen und Institutionen

  • Centre for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital of Lausanne and University of Lausanne, Rue du Bugnon 19, Lausanne, Vaud, 1005, Switzerland, 41 765437675.
  • Department of Clinical Pharmacology, University Hospital of Lausanne and University of Lausanne, Lausanne, Vaud, Switzerland.
  • School of Engineering and Management Vaud, HES-SO University of Applied Sciences and Arts Western Switzerland, Yverdon-les-Bains, Vaud, Switzerland.
  • Bio/CMOS Interfaces Lab, École Polytechnique Fédérale de Lausanne, Lausanne, Vaud, Switzerland.
  • VitalizeDx, Lausanne, Vaud, Switzerland.
  • Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva & Lausanne, Switzerland.

Zitieren

APA

Pétermann, Y. J., Rigamonti, R., Thoueille, P., Chen, J., Alberi, L., Simon, A., Veuve, F., Choong, E., Da Rocha Carvalho, B., Carrara, S., Girardin, F. R., Buclin, T., Csajka, C., Thoma, Y., & Guidi, M. (2026). Safety and Performance Evaluation of a Clinical Decision Support System for Imatinib Therapeutic Drug Monitoring: In Silico Study. JMIR Medical Informatics, 14, e93304-e93304. https://doi.org/10.2196/93304

Vancouver

Pétermann YJ, Rigamonti R, Thoueille P, Chen J, Alberi L, Simon A, et al. Safety and Performance Evaluation of a Clinical Decision Support System for Imatinib Therapeutic Drug Monitoring: In Silico Study. JMIR Medical Informatics. 2026;14:e93304-e93304. doi:10.2196/93304

BibTeX
@article{Ptermann2026,
  author = {Pétermann, Yuan James and Rigamonti, Roberto and Thoueille, Paul and Chen, Junrui and Alberi, Lavinia and Simon, Alexandra and Veuve, François and Choong, Eva and Da Rocha Carvalho, Bruno and Carrara, Sandro and Girardin, François R and Buclin, Thierry and Csajka, Chantal and Thoma, Yann and Guidi, Monia},
  title = {Safety and Performance Evaluation of a Clinical Decision Support System for Imatinib Therapeutic Drug Monitoring: In Silico Study},
  journal = {JMIR Medical Informatics},
  year = {2026},
  volume = {14},
  pages = {e93304--e93304},
  doi = {10.2196/93304}
}
Kostenlos starten →